Search details
1.
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience.
Hematol Oncol
; 41(4): 621-630, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-36680368
2.
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Am J Hematol
; 94(11): 1193-1199, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31378966
3.
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.
Br J Haematol
; 201(2): 353-356, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36793194
4.
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia.
Hematol Oncol
; 41(3): 567-570, 2023 08.
Article
in English
| MEDLINE | ID: mdl-36190298
5.
Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
Future Oncol
; 14(8): 681-697, 2018 Apr.
Article
in English
| MEDLINE | ID: mdl-29243946
6.
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.
Haematologica
; 107(6): 1470-1473, 2022 06 01.
Article
in English
| MEDLINE | ID: mdl-35199505
7.
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.
Hematol Oncol
; 40(5): 1100-1104, 2022 12.
Article
in English
| MEDLINE | ID: mdl-35613703
8.
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
Am J Hematol
; 92(6): 529-535, 2017 Jun.
Article
in English
| MEDLINE | ID: mdl-28295527
9.
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Am J Hematol
; 97(5): E176-E180, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35170793
10.
Health-related quality of life in Waldenstrom Macroglobulinemia and IgM-related disorders: A single institution experience.
Hematol Oncol
; 38(1): 111-113, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-31852014
11.
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines.
Blood Rev
; 65: 101180, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38331696
12.
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.
Cancers (Basel)
; 15(5)2023 Feb 27.
Article
in English
| MEDLINE | ID: mdl-36900295
13.
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Blood Adv
; 7(12): 2794-2806, 2023 06 27.
Article
in English
| MEDLINE | ID: mdl-36696464
14.
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.
Haematologica
; 97(4): 560-7, 2012 Apr.
Article
in English
| MEDLINE | ID: mdl-22102706
15.
SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?
Clin Lymphoma Myeloma Leuk
; 22(6): 356-361, 2022 06.
Article
in English
| MEDLINE | ID: mdl-34969641
16.
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.
Ther Adv Hematol
; 13: 20406207221127550, 2022.
Article
in English
| MEDLINE | ID: mdl-36246422
17.
Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells.
Cancers (Basel)
; 13(8)2021 Apr 12.
Article
in English
| MEDLINE | ID: mdl-33921415
18.
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
Cancers (Basel)
; 13(13)2021 Jun 29.
Article
in English
| MEDLINE | ID: mdl-34209515
19.
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Blood Adv
; 5(24): 5490-5500, 2021 12 28.
Article
in English
| MEDLINE | ID: mdl-34525181
20.
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.
Haematologica
; 100(12): e501-4, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26294723